Ozenoxacin
Jump to navigation
Jump to search
![]() | |
Clinical data | |
---|---|
Pronunciation | oz en ox' a sin |
Trade names | Ozanex; Xepi |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618010 |
License data |
|
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C21H21N3O3 |
Molar mass | 363.417 g·mol−1 |
3D model (JSmol) | |
| |
|
Ozenoxacin, sold under the brand names Ozanex, Ozewid and Xepi, is a quinolone antibiotic used for the treatment of impetigo.[2] A 1% topical cream is approved for treatment of impetigo in Canada[3] and in the United States.[4][5]
Ozenoxacin is active against some bacteria that have developed resistance to fluoroquinolone antibiotics.[6]
References
- ^ "Xepi- ozenoxacin cream". DailyMed. 30 January 2020. Retrieved 13 October 2020.
- ^ Pubchem. "Ozenoxacin". pubchem.ncbi.nlm.nih.gov. Retrieved 2019-01-10.
- ^ "Cipher Pharmaceuticals Receives Health Canada Approval of Ozanex (ozenoxacin cream 1%)" (Press release). Cipher Pharmaceuticals Inc.
- ^ "Medimetriks Pharmaceuticals, Inc. Receives FDA Approval for Xepi (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo" (Press release). Medimetriks Pharmaceuticals, Inc. – via PRNewswire.
- ^ "Xepi (ozenoxacin) Cream". U.S. Food and Drug Administration (FDA). 18 January 2018. Retrieved 13 October 2020.
- ^ López Y, Tato M, Espinal P, Garcia-Alonso F, Gargallo-Viola D, Cantón R, Vila J (Dec 2013). "In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria". Antimicrob Agents Chemother. 57 (12): 6389–6392. doi:10.1128/AAC.01509-13. PMC 3837899. PMID 24080666.
External links
- "Ozenoxacin". Drug Information Portal. U.S. National Library of Medicine.